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Abstract
Background. Current therapies for adenocarcinoma of the pancreas do not improve the life expectancy of pati-
ents. Methods. In a non-randomized pilot trail we tested whether a local therapy based upon an adenoviral gene transfer
of wild type p53 in combination with gemcitabine administration would be safe in patients with liver metastases due to
pancreatic carcinoma. We report on the clinical course of three patients with respect to safety, tolerability and tumor
response. Results. Transient grade III toxicities occurred with fever, leucopenia, elevation of AP, ALT, AST, GGT, while
grade IV toxicity occurred for bilirubin only. Laboratory tests suggested disseminated intravascular coagulation in all three
patients, but fine needle biopsies of liver did not show any histological evidence of thrombus or clot formation. Progression
of liver metastases was documented in one and stable disease in another patient two months after treatment. However, a
major improvement with regression of the indexed lesion by 80% occurred in a third patient after a single administration of
7.5/1012 viral particles, and time to progression was extended to six months. Conclusion. The combination therapy of viral
gene transfer and chemotherapy temporarily controls and diminishes tumor burden. Improvement of the toxicity profile is
necessary. Further trials are warranted to improve treatment and life expectancy of patients suffering from fatal diseases
such as pancreatic carcinoma.
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Introduction
The prognosis of pancreatic carcinoma is poor. Most
patients already have advanced disease at the time of
diagnosis. The 5-year survival rate is around 10% and
depends on the stage, with a median survival of only
6 months [1,2]. Surgery in the form of pancreatico-
duodenectomy offers the only possibility of a cure [3].
However, the 5-year-survival rates after surgery do
not exceed 20% in pancreatic carcinoma [2], due to
early hepatic metastases. Specific mutations in a
number of genes like K-ras, CDKN2A, BRCA2,
SMAD4/DPC4 and p53 have been recognized as
signature lesions involved in and causing progression
of the disease. Among the mutated genes, the p53
tumor suppressor gene is altered in more than 70% of
patients [4,5], which deprives cells of protection
against ill-defined breakage-fusion-bridge cycles, and
allowing for subsequent oncogenic alterations.
Gene transfer therapy could improve the treatment
of pancreatic carcinoma, with adenoviruses being
among the most promising vectors for this therapy
[6]. The transfer of the wild-type tumor suppressor
gene p53 into cancer cells in order to restore its lost
function in DNA damage control was demonstrated
to induce apoptosis in various cells in vitro and in the
mouse model [7], which has prompted its introduc-
tion in antitumor strategies against pancreatic carci-
noma. Indeed, increased tumor cell apoptosis and
reduced cell growth in human pancreatic carcinoma
cell line derived tumors has been demonstrated in
nude mice after adenoviral p53 transfer [8,9]. Like-
wise, an adenoviral vector expressing p21, a down-
stream effector of p53, reduced tumor cell growth,
presumably through reverting cell cycle from S to G0/
G1 phase [10]. Vector-mediated introduction of the
wild-type retinoblastoma gene resulted in growth
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inhibition but not apoptosis [11]. Several other
strategies of gene transfer therapies for pancreatic
carcinoma have been investigated in mice, among
them suicide gene prodrug systems utilizing cytine
deaminase, thymidine kinase or UPRT [1217],
attempts to develop CaSM-antisense strategies [18],
somatostatin receptor transfer [19] or ribozymes that
modulate expression of K-ras [20].
However, a number of limitations dampened early
hopes and have prevented the broader use of gene
transfer therapies. Major among these are the risk of
disseminating viral vectors, and the potential for
severe toxicity sometimes seen with adenoviral vectors
[21]. High doses systemic administration of non-
replicating E1-deleted adenoviral vectors has caused
hepatic necrosis and death in number of animal
models including primates. Especially with increasing
amounts of vector such as might be necessary to
achieve an effective systemic dosage there is evidence
for such toxicity [22,23]. Liver toxicity occurring after
vector administration is substantially milder in repli-
cation incompetent than in replication competent
vectors in animal modeling [24]. However, tolerability
and the level of toxicity observed in phase I and phase
II trials utilizing conditionally replication competent
adenovectors to treat hepatocellular carcinoma or
liver metastases of colorectal cancer have warranted
further trials [25,26]. Still, hepatotoxicity is a major
concern in treating tumors metastatic to the liver.
To date, there is still limited information available
on clinical trials utilizing adenoviral gene transfer for
metastatic pancreatic carcinoma, and few of the
strategies explored in animal modelling have been
evaluated for safety and efficacy in the treatment of
human diseases. We conducted a phase I/II pilot study
to treat patients with liver metastasis due to advanced
pancreatic carcinoma with immunohistologically
proven p53 mutation. An intravenous gemcitabine
chemotherapy was followed on subsequent days
by administration of a p53-expressing, replication
incompetent adenoviral vector rAV/p53 via the coe-
liac artery.
Materials and methods
Study design and patients
A non-randomized, non-controlled, open-label, phase
I/II pilot study of a recombinant replication-defective
and p53-expressing adenoviral vector in combination
with weekly administration of gemcitabine (2’,2’di-
fluorodeoxycytidine) has been initialized in patients
with advanced stage of pancreatic carcinoma.
Patients between the ages of 18 and 75 years with
histologically confirmed and metastatic carcinoma
and stable or progressive disease which was consid-
ered to be incurable have been eligible. Those who
had an identified measurable index lesion, immuno-
histochemical accumulation of p53 as evidence of its
gene mutation, adequate performance status and
laboratory tests and fulfilling all inclusion criteria
were enrolled in the study.
The treatments were conducted as approved by the
ethical board committee of the Dresden University of
Technology. Informed consent was obtained from all
patients prior to treatment. The patients received full
supportive care.
Treatment schedule and vector
Gemcitabine Therapy. The treatment schedule is sum-
marized in Table 1. Gemcitabine (Gemzar, Lilly
Deutschland GmbH, Bad Homburg, Germany) at
1000 mg/m2 was diluted in 100 mL normal saline and
administered intravenously over 30 min once per week
(on day 1, day 8, day 15 etc). In patient 2 and 3 ,
gemcitabine has not been administered on day 8.
Adenoviral Vector and Administration. rAd/p53 (SCH
58500, Essex Pharma GmbH, Mu¨nchen, Germany)
is a serotype 5 based replicationdefective adenoviral
vector. An expression cassette containing the human
cytomegalovirus immediate early promoter and en-
hancer element, the adenovirus serotype 2 tripartite
leader and the human p53 wild type cDNA has been
introduced into region E1 [29]. rAd/p53 was grown
and purified according to standard procedures and
in accordance with GLP/GCP. The IV treatment
Table 1. Treatment Schedule.
Day
Patient Treatment 1 2 3 8 15 22 23 24 29 36 43 50
1 rAd/p53, 2.5/1012 v.p. X X X X
Gemcitabine X X X X X X X X
2 rAd/p53, 2.5/1012 v.p. X X
Gemcitabine X X X X X X X
3 rAd/p53, 7.5/1012 v.p. X
Gemcitabine X X X X X X X
After a single day of Gemcitabine intravenously, rAd/p53 was injected into the celiac artery on the following day(s), followed by 1 d of
intravenous Gemcitabine per week for three weeks.
p53 gene transfer in metastatic pancreatic carcinoma 17
formulation was kindly provided by Schering-Plough
(SCH 58500, Essex Pharma GmbH, Munich,
Germany).
Dosages of 2.5/1012 viral particles twice on
successive days (patients 1 and 2) and in a planned
dose escalation 7.5/1012 (patient 3) were injected
into the coeliac artery in normal saline on days 2 and
3 in all patients and also on days 23 and 24 in patient
1 only. Administration was carried out with radiolo-
gical control via a Terumo sidewinder catheter (5 F,
length 100 cm, inner diameter 0.38 cm). Perfusion
was visualized by injection of 30 mL UltravistTM.
Endpoints, assessment of efficacy and toxicity
Primary Endpoints, Toxicity. Patients were observed to
detect any toxic effects related to any of the categories
within the Common Toxicity Criteria (CTC Version
2.0) such as allergic, haematologic or cardiovascular
complications, coagulopathy, constitutional, gastro-
intestinal, hepatic, infective, metabolic, neurologic,
pulmonary, renal symptoms, pain and tumor lysis
syndrome. Safety was assessed by review of laboratory
studies. All laboratory studies were carried out
according to commercial standard tests and the
manufacturer’s instructions.
Histology. Ultrasound-guided fine-needle aspiration of
the liver was done before and on day 4 after vector
administration. Aspirates were snap-frozen in liquid
nitrogen and stored at /808C. Sections of 8 mm were
fixed in 3% paraformaldehyde in 1/phosphate-
buffered saline (10/PBS: 1.3 M NaCl, 70 mM
Na2HPO4, 30 mM NaH2PO4) prior to staining with
hematoxylin-eosin.
Cryostat sections were immunostained for p53
(DO-1 anti-p53 monoclonal mouse antibody, Dia-
nova, Hamburg, Germany). The specimens were
exposed to the specific antiserum for 12 h at 48C at
dilutions of 1:100. The reaction was visualized using
the avidin-biotin staining method according to the
catalyzed signal amplification (CSA) system (Dako,
Hamburg, FRG) with AEC chromogen (Immuno-
tech, Hamburg, FRG). Slides were counterstained
with hematoxylin, rinsed in water and mounted
in glycerol gelatin (Sigma, Munich, FRG). As a
control, the specific antiserum was replaced by an
isotype-immune serum (Mouse IgG1, k [anti-TNP],
Pharmingen, Hamburg, FRG).
Secondary Endpoint, Assessment of efficacy. The re-
sponse of the index lesion to the treatment was
assessed by thin-layer computed tomography and
positron emission tomography. Positron emission
tomography was performed following a fasting period
of at least 12 h. Scans were obtained over 60 min after
IV injection of approximately 310 MBq 18F-Fluor-
odeoxyglucose. CT examinations were carried out
every month following vector administration with
month 2 examination being evaluated. Positron emis-
sion tomography was added at 2 months in case of
regression or stable disease.
Results
Patient characteristics
Three male patients at 50 years (patient 1), 64 (patient
2), and 58 (patient 3) years of age were included in the
study.
Painless jaundice and weight loss of 10 kg became
apparent in patient 1 two months before enrolment at
the age of 50 years. Ultrasound examinations revealed
a tumor of the head of the pancreas and several lesions
within the liver suggestive of metastases. Histological
examination of an ultrasound guided fine needle
aspiration of a liver lesion revealed a poorly differ-
entiated adenocarcinoma of the pancreas. Jaundice
was treated with biliary prosthesis. The patient had
been enrolled after informed consent was obtained.
The pathological grading and staging was pTx Nx
M1 G3, UICC stage IV. Positive immunoreactivity
against p53 was seen in 90% of cells with 30% poorly,
40% intermediate and 30% strongly positive cells,
corresponding to a Remmele score of 8 and a
Confidential immunoreactivity score (IRS) of 3/.
Patient 2 complained of a lack of appetite, mild
abdominal pain and loss of weight of 8 kg within
4 months prior to diagnosis at 64 years of age.
Helicobacter pylori associated gastritis was treated
without relief of his symptoms. A subsequent com-
puted tomography of the abdomen showed a tumor
of the body of the pancreas and metastases in the
liver. Fine needle aspiration of a liver metastasis
documented an adenocarcinoma of the pancreas.
The patient had been enrolled after informed consent
was obtained.
The tumor was staged and graded histologically as
pTx Nx M1 G3, UICC stage IV. Positive immunor-
eactivity against p53 was seen in 100% of tumor cells.
Exact immunoreactivity scores could not be deter-
mined.
In patient 3 at the age of 58 years cholecystectomy
was performed 9 months before inclusion in the trial.
Three months later the symptoms of dyspepsia,
diarrhoea and meteorism recurred and were accom-
panied by weight loss of 7 kg. Four months later he
was diagnosed with a tumor in the head of the
pancreas and underwent a partial duodenopancrea-
tectomy (Whipple’s procedure). Pathology examina-
tion revealed a mildly differentiated tubulo-papillous
adenocarcinoma of the pancreas. Five months later
metastases in the liver were found. The patient was
enrolled after informed consent was obtained.
The pathological grading and staging was pT2 N0
M0 G2 RO, UICC stage I, at the time of surgery.
Positive p53 immunoreactivity was seen in 40% of
cells with 50% poorly, 40% intermediate and 10%
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strongly positive cells among these, thus resembling a
Remmele score of 2 and Confidential IRS of 2/.
After inclusion of three patients the study was
halted because of safety concerns arising after a
fatality that occurred in a human subject participating
in a clinical trial for ornithine transcarbamylase
deficiency [27,28] and observed grade III and grade
IV toxicities in our own trail, and no further patients
were treated in this protocol.
Assessment of toxicity
General performance and constitutional symptoms of
patients. All patients had a Karnofsky index of 80%
or higher, the BMI ranged between 22.3 and 23.8
(patient 1, 73 kg bodyweight at 181 cm height; patient
2, bodyweight 69 kg and 172 cm body height; patient
3 bodyweight 67.7 kg and 175 cm body height).
Patients 1 & 2 developed chills and an increase of
body temperature not exceeding 38.58C. No immedi-
ate rise in body temperature was seen in patient 3 ,
however, on day 8 he experienced convulsive abdom-
inal pain accompanied by shivers and a temperature
increase to 40.58C 8 d after vector administration.
The symptoms have been suggested to be related to
bacterial cholangitis due to insufficiency of bile stent
and resolved after change of the stent and adminis-
tration of ciprofloxacin.
Cardiovascular. For all patients blood pressure and
heart rate remained within the normal range after
vector administration and on the following days. In
patients 1 and 3 a slight decrease in blood pressure not
falling below systolic 105 mmHg and diastolic
80 mmHg was observed upon immediate administra-
tion. The heart rate remained within the normal
range, and no cardiovascular support was needed.
Hepatic toxicity. All patients showed an elevation of
serum AST between 2.1 and 5.5 times (maximum
5.51 mmol/L*s) and of serum ALT between 1.38 and
2.8 times (maximum 3.85 mmol/L*s) compared to
values before treatment (Figure 1). Total bilirubin
levels ranged between 13.6 and 24 mmol/L, with a
tendency to increase during progression of the disease
and without notable impact of the administered
therapy. A 2.5 fold increase (14,37 mmol/L*s) in
lactate dehydrogenase was seen only in patient 3,
who received the highest dose. Total protein and
serum albumin decreased during the first 4 d, with
minimal values when ALT and AST elevation reached
maximum values. However, the total protein and
serum albumin did not fall below the normal range.
There have been no clinical signs of hepatic encepha-
lopathy.
Coagulation profile. All patients showed a slight de-
crease of thromboplastin time. In two patients partial
thromboplastin time increased up to 1.9 times above
the upper limit of normal. Disseminated intravascular
coagulation was present in all three patients as defined
by elevation of D-dimers. D-dimers increased above
the upper limit of normal (below 1,0 mg/mL) up to
4 fold in patient 1 (4,0 mg/mL), 1.9 fold in patient 2
(1,9 mg/mL) und 8 fold in patient 3 (8,0 mg/mL).
Blood. In all patients a decline in blood components
was observed. Only in patient 3 , who received highest
dosage leukocytes fall to 1.9/109 /L and platelets to
66/109 /L.
Tumor lysis syndrome and related. Tumor lysis syn-
drome was absent in the patients. No apparent
changes in kidney parameters were observed. The
data is summarized in Table 2.
Histological findings. On day 4 after vector administra-
tion, fine needle aspiration of liver metastases was
performed. The specimens demonstrated a mild to
moderate fatty degeneration of hepatocytes with
anisonucleosis, slight cholestasis as well as chronic
inflammation of the portal fields and within the lobuli.
Of note, smaller arteries and portal vessels and
sinusoids were devoid of histological signs of epithelial
damage or thrombus formation. Besides this, necrotic
cell clusters within the initial carcinomatous tissue
were present (Figure 2).
Assessment of efficacy
Efficacy of treatment was evaluated using thin layer
computed tomography and positron emission tomo-
graphy scan examinations.
Patient 1. Computed tomography showed stable dis-
ease 2 months after vector administration. Positron
emission tomography suggested decreased metabolic
activity of the metastases. Radiologic and clinical
progression were confirmed 3 months after vector
administration.
Patient 2. Progression of liver metastases had to be
confirmed after 2 months by computed tomography
examinations. No further therapy was given.
Patient 3. Regression of liver metastases was confirmed
in computed tomography 2 months after vector
administration. The size of the index lesion decreased
by 38% (from 31 mm/24 mm to 22 mm/21 mm).
Likewise, a major improvement was demonstrated by
positron emission tomography. The therapy was
continued only with gemcitabine due to the closure
of the trial; after 4 months computed tomography
documented further regression of the index lesion
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to /80% of initial size (13/12 mm), but 6 months
later the patient experienced progression of disease.
Data are depicted in Figure 3.
Discussion
We conducted a phase I/II pilot trial of adenoviral
transfer of wild type p53 into hepatic metastases of
pancreatic carcinoma in combination with weekly
gemcitabine administration. Coeliac arterial infusion
of the p53-expressing replication-incompetent adeno-
virus derivative was well tolerated at doses resulting in
therapy-associated antitumor activity. Constitutional
symptoms related to vector administration consisted
of fever and chills only, as has been reported in other
clinical trials [3032]. Other side effects have been
observed for blood cells and platelets, liver chemistry
and the coagulation profile.
Thrombocytopenia and leukopenia occurred at a
maximum around 4 d after vector administration.
This early cytopenia could not be linked to the
additional administration of gemcitabine as it did
not recur after following cycles of gemcitabine admin-
istration, and marrow toxicity would not be expected
before 810 d after treatment. Similar cytotoxic
effects have been reported in a trial of sonographically
guided intratumoral Adv.RSV-tk injection and intra-
venous ganciclovir for treatment of colorectal cancer
metastatic to the liver [33]. An immediate consump-
tion might be expected and has been suggested
because of observations from other trials and animal
models. Vector administration to nonhuman primates
has demonstrated a saturable and reversible decrease
in platelet halflife [34,35]. However, adenoviral vec-
tors have been used to transduce platelets and
megakaryocytes efficiently [36,37], and vectors ex-
pressing fibroblast growth factor 4 or thrombopoietin
can significantly increase platelet counts in animal
models [38,39], which strongly suggests that there is
no direct inadvertent effect of adenoviral vectors on
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Figure 1. Blood cell count and blood chemistry after administration of rAd/p53. Elevation of liver enzymes and bilirubin occurred in all
three patients albeit at differing levels and returned to pretreatment levels depending an degree of liver infiltration [3 Units and symbols for
liver chemistry as follows: j ALAT in mmol/L*s, I ASAT in mmol/L*s, ' GGT in mmol/L*s, ^ total Biliribin in mmol/L]. Transient
alterations of coagulation profile in all three patients and indication of permanent impairement most likely due to altered liver function upon
metastases [2 Units and symbols for coagulation profile as follows: j Quick in %, I PTT in sec, ' Fibrinogen g/L, ^ ATIII in %]. The
drop in platelets and white blood cells was transient [1 Units and symbols for coagulation profile as follows: j Hemoglobin in mmol/L,
I WBC in GPt/L, * Platelets in GPt/L; % or %% indicate single or repeated injections of vector].
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platelets. In fact, ex vivo experiments demonstrate
that adenovirus does not enhance platelet aggregation
upon direct interaction nor does it interfere with ADP,
collagen, or epinephrine-induced platelet activation
[40]. Hence, the explanation as to why adenoviral
vectors did induce this notable drop in platelets as
reported in the trials has yet to be determined.
Patients developed laboratory signs of disseminated
intravascular coagulation. According to the applied
CTC criteria, increased fibrin split products or D-
dimers characterize disseminated intravascular coagu-
lation. Additionally, we noted a decline in AT III and
thromboplastin time and a prolongation of partial
thromboplastin time, all of which accord with acti-
vated intravascular coagulation. In spite of the altered
laboratory tests and even in combination with the low
platelets, none of the patients developed petechiae or
other signs of bleeding disorders.
Elevation of liver enzymes and parameters of
cholestasis occurred in all three patients albeit to
varying degrees. Elevation of liver enzymes is common
in diseases metastatic to the liver, and  therefore 
their evaluation is not unequivocal. In two of our three
patients, serum levels of ASAT, ALAT, GGT and
Table 2. Summary of toxicities observed.
CTC Grade
Patient 1 Patient 2 Patient 3
Constitutional and gastrointestinal symptoms
Fever (with AGC /1.0/109/L) 0 0 [0] 3%
chills [0] 1 [0] 1 [0] 1%
Nausea 0 0 [0] 2%
Vomiting 0 0 [0] 1%
Diarrhea 0 0 0
Pain
Myalgia (muscle pain) 0 0 0
Abdominal pain or cramping [0] 1 [0] 1 [0] 2%
Chest pain (non-cardiac and non-pleuritic) 0 0 0
Hepatic pain 0 0 [0] 1%
Cardiovascular/allergy/infection
Acute vascular leak syndrome 0 0 0
Hypertension 0 0 0
Allergic reaction/ hypersensitivity 0 0 0
Infection 0 0 [0] 2%
Hepatic
Bilirubin [1] 2, later 4 [1] 4 [0] 2%
Alkaline phosphatase [2] 2 [3] 3 [1] 2%
GGT (Glutamyl transpeptidase) [2] 3 [3] 3 [2] 3
SGPT (ALAT) [1] 2 [2] 3 [1] 2
Hypoalbuminemia 0 0 0
SGOT (ASAT) [1] 2 [2] 3 [1] 3
Clinical signs of liver dysfunction* 0 0 0
Tumor lysis syndrome and related
Tumor lysis syndrome 0 0 0
Creatinine 0 0 0
Hypercalcemia 0 [0] 2 0
Hyperkalemia 0 0 0
Hyperuricemia 0 0 0
Coagulation
Fibrinogen 0 0 0
Partial thromboplastin time (PTT) 0 [0] 2 [0] 2
Thromboplastin time8 0 [0] 1 0
DIC (disseminated intravascular coagulation)$ [0] 3 [0] 3 [0] 3
Thrombosis 0 0 0
Blood
Hemoglobin [0] 1 [0] 1 0
Leukocytes 0 0 [0] 3
Platelets 0 [0] 1 [0] 2
The highest toxicity was documented between days 4 and 6 ([/] the number in brackets represents toxicity grade if CTC criteria were
applied before treatment was initiated; * asterixis, encephalopathy or coma; $ defined by increased fibrin split products or D-dimer;
% occurring 8 d after treatment and suggested to be related to bacterial cholangitis due to insufficiency of bile stent; 8 Thromboplastin time:
Grade 0 within normal limits, grade 1 0.75B/1.0/lower limit of normal; grade 2 0.5B/0.75/lower limit of normal; grade 3 0.25
B/0.5/lower limit of normal; grade 4 B/0.25/lower limit of normal).
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bilirubin returned or nearly returned to pretreatment
levels which is comparable to trials utilizing replica-
tion-incompetent and replication-selective oncolytic
vectors [25,41]. The elevation of liver enzymes started
soon after infection and most likely indicated infection
and death of hepatocytes due to viral hepatitis.
Indeed, increased expression of beta 2-microglobulins
and HLA-DR antigens in hepatocytes together with
infiltration with CD3(/), CD4(/) and CD8(/)
T-lymphocytes, resembling a mild and transient viral
hepatitis after receiving adenovirus was found in
animal modeling [42]. Severe inflammation of the
liver including death of laboratory animals was seen in
other models and was dependent on the dosage of
vector and on its ability to undergo replicative cycles
[21,24].
A possible explanation for most of the observed
phenomena could be the initial damage to endothelial
and Kupffer cells. Endothelial damage and activation
will subsequently activate coagulation and platelet
aggregation. Recent data suggest that transduction is
different for the three major cell populations compos-
ing the liver, Kupffer cells, endothelial cells and
hepatocytes, with endothelial and Kupffer cells being
more efficiently infected; and even clearance and
sequestration of blood from adenoviral vector by
Kupffer cells has been described [43,44]. Interaction
of viral particles with Kupffer cells could then activate
the endothelium by paracrine cytokine effects [45].
Notably, systemic cytokine release through inadver-
tent targeting of such antigen-presenting cells is
probably triggered by the viral capsid proteins
Figure 2. Histologic presentation at day 4 after vector administra-
tion. The vessels have been devoid of histological signs of epithelial
damage or thrombus formation (patient 2 ; 400/).
Figure 3. Computed tomography and positron emission tomography scan examinations before and two months after administration of rAd/
p53. In patient 1 (ad), stable disease was documented after 2.5 / 1012 on days 2 and 3 and 23 and 24. Necrotic enhancement of the edge
of the metastases (b). A slight reduction in 18F-Fluorodeoxyglucose activity suggests reduced metabolic activity of metastases (d). In patient
2 (eg), progression was revealed in CTexamination, therefore, no PET scan was obtained after two months. In patient 3 (hk), regression
of liver metastasis (arrows) was confirmed in computed tomography (h,i) and a major improvement was demonstrated in positron emission
tomography (j,k) after administration of the adenoviral vector.
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[46,47], and the depletion of liver from macrophages
increases hepatic transgene expression and reduces
the immunologic response [44]. Thus, Kupffer and
endothelial cell damage might be the primary event
triggering a cascade of events involving injury and
death of cells, the release of mediators of inflamma-
tion and immune activation. In our patients we failed
to histologically detect any endothelial damage or
coagulation within the smallest vessels of the liver.
Endothelial damage itself has been linked to the
release of cytokines which, in turn, have been reported
from animal models to cause an immediate drop in
blood pressure and increase in heart rate [45,48]. In
our patients we observed an immediate, but only
slight, decrease in blood pressure in only two of three
patients, while their heart rate remained constant; no
supportive measures had to be taken. However, a
severe systemic inflammatory response syndrome,
disseminated intravascular coagulation, and multiple
organ failure was observed in an 18-year old male
participant in a clinical trial which finally led to the
death of the patient [28]. The inflammatory response
to adenovirus vector administration is not restricted to
the liver solely, since a varying level of inflammatory
cytokine response was observed with various routes of
administration including airway and myocardial ad-
ministration [49] and cytokine release from mono-
nuclear cells has been observed ex vivo [46].
We saw a major improvement in a patient receiving
7.5/1012 PFU of rAd/p53 and stable disease in a
patient receiving 2.5/1012 PFU on days 2, 3 and 23,
24 in combination with gemcitabine chemotherapy.
Clinical trials using hepatic artery, intravenous or
intratumoral infusion as the route of administration
have reported antitumor activity and mild toxicity
[25,26,50]. In a previous trial utilizing endoscopic
ultrasound-guided transgastric delivery of ONYX-
015 into unresectable pancreatic carcinomas 10 of
21 patients responded to treatment in combination
with gemcitabine [51], and 17 out of 23 patients had
mixed tumor responses after CT-guided injection of
ONYX-015 [52]. In a further study of administration
of 4/107 to 4/1011 viral particles of a TNF-a
exprssing adenovector (TNFerade) that included
patients with pancreatic carcinoma, a tumor response
was documented in 3 out of 6 patients [53]. Only
limited data is available concerning long term survival
in trials utilizing p53 transfer. However, a median
survival of 12 to 13 months compares favorably to a
5-month survival seen with palliative radiotherapy or
paclitaxel failure in heavily pretreated patients with
recurrent ovarian cancer [54].
To date, there is still limited information available
on clinical trials utilizing adenoviral gene transfer
strategies for metastatic pancreatic carcinoma, and
few of the strategies explored in animal modelling
have been evaluated for safety and efficacy in the
treatment of the human disease. In summary, our
study involving three patients who received a combi-
nation therapy of viral gene transfer and chemother-
apy shows some potential in temporarily controlling
and even diminishing tumor burden in one patient.
The side effects and toxicity observed in our trial were
mild and well tolerated. Further trials are warranted
in an effort to improve the treatment and life
expectancy of patients suffering from fatal diseases
such as pancreatic carcinoma.
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